Clinical Trials Logo

Endometrial Cancer clinical trials

View clinical trials related to Endometrial Cancer.

Filter by:

NCT ID: NCT00118300 Withdrawn - Ovarian Cancer Clinical Trials

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer

Start date: April 2005
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with radiation therapy in treating patients with locally advanced cervical cancer or other pelvic cancer.

NCT ID: NCT00099008 Completed - Breast Cancer Clinical Trials

Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women

Start date: March 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of genistein may be effective in preventing breast or endometrial cancer. PURPOSE: This randomized phase I trial is studying the effectiveness of genistein in preventing breast or endometrial cancer in healthy postmenopausal women.

NCT ID: NCT00096408 Completed - Endometrial Cancer Clinical Trials

Laparoscopic Approach to Cancer of the Endometrium

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess disease-free survival at 4.5 years postoperatively for women with apparent Stage 1 endometrial cancer, comparing patients who are randomised to receive Total Laparoscopic Hysterectomy (TLH) and patients who are randomised to receive Total Abdominal Hysterectomy (TAH).

NCT ID: NCT00087685 Completed - Endometrial Cancer Clinical Trials

RAD001 in Recurrent Endometrial Cancer Patients

Start date: June 2004
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if RAD001 can shrink or slow the growth of tumors in patients who have recurrent endometrial cancer. The safety of this drug will also be studied. Objectives: Primary Objective: 1. To determine the efficacy of RAD001 in patients with progressive or recurrent endometrial cancer. Secondary Objective: 1. To determine the nature and degree of toxicity of RAD001 in this cohort of patients. 2. To characterize, in pre- and post- treatment tumor samples, when available, expression levels of total and phosphorylated mTOR (mammalian "target of rapamycin") as well as relevant upstream and downstream signaling components (optional).

NCT ID: NCT00087100 Completed - Endometrial Cancer Clinical Trials

Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer

Start date: May 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy such as pemetrexed disodium work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with persistent or recurrent endometrial cancer.

NCT ID: NCT00085332 Completed - Endometrial Cancer Clinical Trials

Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)

Start date: July 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well docetaxel works in treating patients with recurrent or persistent endometrial carcinoma (cancer).

NCT ID: NCT00072176 Completed - Clinical trials for Endometrial Adenocarcinoma

Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well temsirolimus works in treating patients with endometrial cancer that has spread to other parts of the body or has spread from where it started to nearby tissue or lymph nodes and has come back after a period of time during which the cancer could not be detected. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00071929 Completed - Endometrial Cancer Clinical Trials

Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer

Start date: November 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have persistent or recurrent endometrial cancer.

NCT ID: NCT00064025 Completed - Endometrial Cancer Clinical Trials

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Start date: October 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer. PURPOSE: This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix).

NCT ID: NCT00053794 Completed - Sarcoma Clinical Trials

Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma

Start date: June 9, 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have metastatic or locally advanced soft tissue sarcoma.